This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1399 entries already.
Orano Med and Roche have launched a clinical development programme for CEA‑targeted two‑step PRIT using lead‑212, with Orano supplying the ²¹²Pb, while Novartis and ITM are expanding production of alpha‑emitting radiopharmaceuticals.
After four EU Council presidencies, EU member states and the European Parliament yesterday struck a provisional deal on new genomic techniques under the current Danish presidency, setting clear rules to boost agrifood innovation, plant resilience, transparency and sustainability.
Clascoterone 5% topical solution has demonstrated significant hair growth in Phase III trials, showing strong efficacy and a favourable safety profile in men with androgenetic alopecia.
After the withdrawal of investment pledges totalling £2bn by pharmaceutical companies — seeking to offset lower US revenue by raising UK prices — the British government has now caved in and signed a deal with the US administration that will lift UK drug prices by 25%
The European Investment Bank (EIB) and Angelini Ventures, the corporate venture capital arm of Angelini Industries, have signed an agreement to jointly provide €150m over the next six years to support European biotechnology and digital health start-ups through seven to ten funding rounds. This marks the EIB’s first partnership with a corporate venture capital firm in Europe’s health sector under its TechEU programme.
A month after China publicly revealed its bioeconomy priorities under its 15th Five Year Plan, the European Commission released an updated EU Bioeconomy Strategy — and the contrast could hardly be sharper. While China bets on a bold mix of AI, bioengineering and synthetic biology to replace fossil based industrial products with recombinant and cell free systems, the EU remains anchored in a more traditional vision focused on the valorisation of agricultural output and industrial waste. By contrast, the UK has taken a more modern approach, heavily investing in engineering biology — the use of reprogrammed microorganisms to produce industrial goods — as a key pillar of its biotech and bioeconomy strategy.
French Afyren secures €23m to accelerate biorefinery expansion as first plant enters full industrial ramp-up. Most of the money comes from US company Kemin Industries.
Lyon-based Ventuno Biotech secures fresh backing to accelerate its preclinical pipeline of first-in-class immuno-oncology assets.
Novo Nordisk’s semaglutide has failed to reduce the cognition deficit in two Phase III Alzheimer’s trials, dimming GLP-1 hopes. Anti-amyloid and combination therapies remain key for slowing decline.
Sprint Bioscience AB has sold its preclinical TREX1 first-in-class cancer program to Gilead for up to US$414m, validating its fragment-driven small-molecule out-licensing business model.